The short version of lyophilized powder fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-06-18 and is reviewed periodically as new material appears.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid as supplied |
| Water solubility | Soluble | Dissolves in aqueous media |
| Typical storage temperature | -20 °C | Dry powder, desiccated, protected from light |
| Typical analytical method | RP-HPLC with mass spectrometry | Purity from peak area; mass for identity |
| Common synonyms | Tβ4 fragment; thymosin beta-4 fragment | Naming varies by supplier and catalogue |
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
The two substrates of this enzyme are (R,R)-butane-2,3-diol and NAD+; its products are (R)-acetoin, nicotinamide adenine dinucleotide (NADH), and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is (R,R)-butane-2,3-diol:NAD+ oxidoreductase. Other names in common use include butyleneglycol dehydrogenase, D-butanediol dehydrogenase, D-(−)-butanediol dehydrogenase, butylene glycol dehydrogenase, diacetyl (acetoin) reductase, D-aminopropanol dehydrogenase, D-aminopropanol dehydrogenase, 1-amino-2-propanol dehydrogenase, 2,3-butanediol dehydrogenase, D-1-amino-2-propanol dehydrogenase, (R)-diacetyl reductase, (R)-2,3-butanediol dehydrogenase, D-1-amino-2-propanol:NAD+ oxidoreductase, 1-amino-2-propanol oxidoreductase, and aminopropanol oxidoreductase. This enzyme participates in butanoic acid metabolism.
== Pathophysiology == Scleroderma is characterised by increased synthesis of collagen (leading to the sclerosis), damage to small blood vessels, activation of T lymphocytes, and production of altered connective tissue. Its proposed pathogenesis is the following:
{\displaystyle K={\frac {[\mathrm {S} ]^{\sigma }[\mathrm {T} ]^{\tau }...}{[\mathrm {A} ]^{\alpha }[\mathrm {B} ]^{\beta }...}}\times {\frac {{\gamma _{\mathrm {S} }}^{\sigma }{\gamma _{\mathrm {T} }}^{\tau }...}{{\gamma _{\mathrm {A} }}^{\alpha }{\gamma _{\mathrm {B} }}^{\beta }...}}=K_{\mathrm {c} }\Gamma }
By human standards, dinosaurs were creatures of fantastic appearance and often enormous size. As such, they have captured the popular imagination and become an enduring part of human culture. The entry of the word "dinosaur" into the common vernacular reflects the animals' cultural importance: in English, "dinosaur" is commonly used to describe anything that is impractically large, obsolete, or bound for extinction. Public enthusiasm for dinosaurs first developed in Victorian England, where in 1854, three decades after the first scientific descriptions of dinosaur remains, a menagerie of lifelike dinosaur sculptures was unveiled in London's Crystal Palace Park. The Crystal Palace dinosaurs proved so popular that a strong market in smaller replicas soon developed. In subsequent decades, dinosaur exhibits opened at parks and museums around the world, ensuring that successive generations would be introduced to the animals in an immersive and exciting way. The enduring popularity of dinosaurs, in its turn, has resulted in significant public funding for dinosaur science, and has frequently spurred new discoveries. In the United States, for example, the competition between museums for public attention led directly to the Bone Wars of the 1880s and 1890s, during which a pair of feuding paleontologists made enormous scientific contributions. The popular preoccupation with dinosaurs has ensured their appearance in literature, film, and other media.
==== Compatibility and feature support ==== All DisplayPort cables are compatible with all DisplayPort devices, regardless of the version of each device or the cable certification level. All features of DisplayPort will function across any DisplayPort cable. DisplayPort does not have multiple cable designs; all DP cables have the same basic layout and wiring, and will support any feature including audio, daisy-chaining, G-Sync/FreeSync, HDR, and DSC. DisplayPort cables differ in their transmission speed support. DisplayPort specifies seven different transmission modes (RBR, HBR, HBR2, HBR3, UHBR 10, UHBR 13.5, and UHBR 20) which support progressively higher bandwidths. Not all DisplayPort cables are capable of all seven transmission modes. VESA offers certifications for various levels of bandwidth. These certifications are optional, and not all DisplayPort cables are certified by VESA. Cables with limited transmission speed are still compatible with all DisplayPort devices, but may place limits on the maximum resolution or refresh rate available. DisplayPort cables are not classified by "version". Although cables are commonly labeled with version numbers, with HBR2 cables advertised as "DisplayPort 1.2 cables" for example, this notation is not permitted by VESA. The use of version numbers with cables can falsely imply that a DisplayPort 1.4 display requires a "DisplayPort 1.4 cable", or that features introduced in version 1.4 such as HDR or DSC will not function with older "DP 1.2 cables".
Sources: en.wikipedia.org
== Climate == The climate of Stanley is classified as a subpolar oceanic climate (Köppen Cfc), bordering very closely on a polar climate (ET). Nowadays it barely avoids classification as ET because the mean temperature is greater than 10 °C (50 °F) for two months of the year. Unlike typical tundra climates, however, the winters are very mild, and vegetation grows there that normally could not in a climate this close to a polar climate. Contrast this with Churchill, Manitoba, which also has a near-tundra climate but is much more continental in nature. The Falkland Islands have displayed a warming trend in recent years; the mean daily January maximum for Mount Pleasant for the years 1999-2012 is 15.1 °C (59.2 °F) compared to Stanley's 1961-90 average of 14.1 °C (57.4 °F). Formerly, Stanley had a tundra climate (ET), due to cool summer temperatures (the mean temperature was less than 10 °C or 50 °F in the hottest month). Like the rest of the archipelago, Stanley has more or less even temperatures through the year and strong westerlies. Precipitation, averaging 544 mm (21.42 in) a year, is nonetheless relatively low, and evenly spread throughout the year. Typically, at least 1 mm (0.039 in) of rain will be recorded on 125.2 days of the year. The islands receive 36.3% of possible sunshine, or around 1500–1600 hours a year, a level similar to southern parts of England. Daytime temperatures are similar to the Northern Isles of Scotland, though nights tend to be somewhat colder, with frost occurring on more than 1 in 3 nights (128.4 nights). Snow occurs in the winter.
== Early life and education == De Duve was born of an estate agent Alphonse de Duve and wife Madeleine Pungs in the village of Thames Ditton, near London. His parents fled Belgium at the outbreak of the First World War. After the war in 1920, at age three, he and his family returned to Belgium. He was a precocious boy, always the best student (primus perpetuus as he recalled) in school, except for one year when he was pronounced "out of competition" to give chance to other students. He was educated by the Jesuits at Onze-Lieve-Vrouwinstituut in Antwerp, before studying at the Catholic University of Louvain in 1934. He wanted to specialize in endocrinology and joined the laboratory of the Belgian physiologist Joseph P. Bouckaert, whose primary interest was one insulin. During his last year at medical school in 1940, the Germans invaded Belgium. He was drafted to the Belgian army, and posted in southern France as medical officer. There, he was almost immediately taken as prisoner of war by Germans. His ability to speak fluent German and Flemish helped him outwit his captors. He escaped back to Belgium in an adventure he later described as "more comical than heroic". He immediately continued his medical course, and obtained his MD in 1941 from Leuven. After graduation, de Duve continued his primary research on insulin and its role in glucose metabolism. He (with Earl Sutherland) made an initial discovery that a commercial preparation of insulin was contaminated with another pancreatic hormone, the insulin antagonist glucagon.
In 2009, the PLA held its first military exercise in Africa, a humanitarian and medical training practice conducted in Gabon. For the past 10 to 20 years, the PLA has acquired some advanced weapons systems from Russia, including Sovremenny-class destroyers, Sukhoi Su-27 and Kilo-class diesel-electric submarines. It has also started to produce several new classes of destroyers and frigates including the Type 052D class guided-missile destroyer. In addition, the PLAAF has designed its very own Chengdu J-10 fighter aircraft and a new stealth fighter, the Chengdu J-20. The PLA launched the new Jin class nuclear submarines on 3 December 2004 capable of launching nuclear warheads that could strike targets across the Pacific Ocean and have three aircraft carriers, with the latest, the Fujian, launched in 2022. From 2014 to 2015, the PLA deployed 524 medical staff on a rotational basis to combat the Ebola virus outbreak in Liberia, Sierra Leone, Guinea, and Guinea-Bissau. As of 2023, this was the PLA's largest medical assistance mission in another country. China re-organized its military from 2015 to 2016. In 2015, the PLA formed new units including the PLA Ground Force, the PLA Rocket Force, and the PLA Strategic Support Force. In 2016, the CMC replaced the four traditional military departments with a number of new bodies. China replaced its system of seven military regions with newly established Theater Commands: Northern, Southern, Western, Eastern, and Central. In the prior system, operations were segmented by military branch and region.
== Function == GGT6 belongs to the gamma-glutamyltransferase (GGT; EC 2.3.2.2) gene family. GGT is a membrane-bound extracellular enzyme that cleaves gamma-glutamyl peptide bonds in glutathione and other peptides and transfers the gamma-glutamyl moiety to acceptors. GGT is also key to glutathione homeostasis because it provides substrates for glutathione synthesis (Heisterkamp et al., 2008 [PubMed 18357469]).
Sources: en.wikipedia.org
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.
The parent protein contains forty-three amino acids, while the fragment carries only a short motif from one region. The fragment can interact with actin in vitro, but it does not include the rest of the protein structure. Whether the shorter molecule behaves the same way in living systems is not settled.
Published controlled human studies are scarce, and most activity reports come from cell culture or animal models. Reviews often describe the evidence base as limited and methodologically uneven. Open questions include the relationship between route, dose, and measured outcomes.
The most common approach is liquid chromatography with tandem mass spectrometry after extraction from blood or urine. Immunoassays exist but are generally treated as screening tools because of cross-reactivity.